New combo vaccine aims to shield seniors from two respiratory viruses
NCT ID NCT06583031
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 24 times
Summary
This early-stage study tested a new vaccine designed to protect against two respiratory viruses: RSV and hMPV. It involved 385 healthy adults aged 60 to 75 who received a single shot of different vaccine doses. The main goals were to check the vaccine's safety and see how well it triggers the immune system to fight these viruses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site # 031001
Brookvale, New South Wales, 2100, Australia
-
Site # 0361002
Wollongong, New South Wales, 2500, Australia
-
Site # 0361003
Herston, Queensland, 4006, Australia
-
Site # 0361004
Botany, New South Wales, 2019, Australia
-
Site # 0361005
South Brisbane, Queensland, 4101, Australia
-
Site # 0361006
Miranda, New South Wales, 2228, Australia
Conditions
Explore the condition pages connected to this study.